RhumbLine Advisers
DNTH icon

RhumbLine Advisers’s Dianthus Therapeutics DNTH Stock Holding History

RhumbLine Advisers’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.7M Buy
58,521
+13,335
+30% +$1.16M ﹤0.01% 1411
2026
Q1 		$3.79M Buy
45,186
+14,157
+46% +$820K ﹤0.01% 1537
2025
Q4 		$1.28M Buy
31,029
+5,026
+19% +$195K ﹤0.01% 2099
2025
Q3 		$1.02M Sell
26,003
-5,498
-17% -$141K ﹤0.01% 2224
2025
Q2 		$587K Sell
31,501
-3,544
-10% -$66.5K ﹤0.01% 2587
2025
Q1 		$636K Sell
35,045
-888
-2% -$19.6K ﹤0.01% 2410
2024
Q4 		$783K Buy
35,933
+1,316
+4% +$33.8K ﹤0.01% 2375
2024
Q3 		$948K Buy
34,617
+2,479
+8% +$69K ﹤0.01% 2287
2024
Q2 		$832K Buy
+32,138
New +$773K ﹤0.01% 2341
2022
Q2 		– Sell
-1,564
Closed -$73K – 3133
2022
Q1 		$73K Buy
1,564
+28
+2% +$1.53K ﹤0.01% 2940
2021
Q4 		$109K Sell
1,536
-11
-0.7% -$1.11K ﹤0.01% 2933
2021
Q3 		$180K Sell
1,547
-127
-8% -$14.8K ﹤0.01% 2925
2021
Q2 		$262K Buy
1,674
+128
+8% +$23.5K ﹤0.01% 2834
2021
Q1 		$293K Sell
1,546
-39
-2% -$6.56K ﹤0.01% 2702
2020
Q4 		$199K Buy
1,585
+335
+27% +$38K ﹤0.01% 2841
2020
Q3 		$136K Sell
1,250
-103
-8% -$12.2K ﹤0.01% 2802
2020
Q2 		$163K Sell
1,353
-20
-1% -$2.82K ﹤0.01% 2845
2020
Q1 		$138K Hold
1,373
– – ﹤0.01% 2701
2019
Q4 		$333K Buy
1,373
+12
+0.9% +$2.24K ﹤0.01% 2545
2019
Q3 		$223K Sell
1,361
-13
-0.9% -$2.47K ﹤0.01% 2708
2019
Q2 		$324K Buy
1,374
+415
+43% +$103K ﹤0.01% 2570
2019
Q1 		$253K Buy
+959
New +$165K ﹤0.01% 2630

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

RhumbLine Advisers's DNTH Position: Q2 2026 in Review

RhumbLine Advisers increased its Dianthus Therapeutics (DNTH) stake by 30% in Q2 2026, buying an estimated $1.16M and bringing the position to 58,521 shares worth $5.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1411.

RhumbLine Advisers first reported a position in DNTH in Q1 2019 and has held it in 22 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • RhumbLine Advisers held 58,521 shares of Dianthus Therapeutics worth $5.7M as of Q2 2026.
  • RhumbLine Advisers bought 13,335 Dianthus Therapeutics shares in Q2 2026, an estimated $1.16M.
  • Dianthus Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1411 holding.
  • RhumbLine Advisers first reported a position in Dianthus Therapeutics in Q1 2019 and has held it in 22 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.